ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and remains the leading cause of cancer-related death. Our understanding of the nature and biology of lung cancer continues to increase as does the notion that NSCLC does not represent a single disease entity, but rather is a collection of diseases with different histologic and genetic subtypes.